BioMarin Pharma Reports Officer/Director Changes
Ticker: BMRN · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 B, $460,000, $400,000, $1,050,000, $450,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
Related Tickers: BMRN
TL;DR
BioMarin's 8-K details leadership changes and executive pay adjustments.
AI Summary
BioMarin Pharmaceutical Inc. filed an 8-K on December 17, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not elaborated in the provided text.
Why It Matters
Changes in key leadership and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially concerning compensatory arrangements, can introduce uncertainty about future strategy and leadership stability.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- December 11, 2025 (date) — Date of earliest event reported
- December 17, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in the excerpt.
What is the nature of the compensatory arrangements mentioned?
The filing states that there are compensatory arrangements for certain officers, but the details of these arrangements are not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was as of December 11, 2025.
What is BioMarin Pharmaceutical Inc.'s state of incorporation?
BioMarin Pharmaceutical Inc. is incorporated in Delaware.
What is the principal executive office address for BioMarin?
The principal executive offices are located at 770 Lindaro Street, San Rafael, California, 94901.
Filing Stats: 953 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-12-17 16:06:46
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market I
- $460,000 — the following: (i) an annual salary of $460,000 (Base Salary); (ii) a sign-on bonus of
- $400,000 — (Base Salary); (ii) a sign-on bonus of $400,000 (the Sign-on Bonus); (iii) the right to
- $1,050,000 — restricted stock units (RSUs) valued at $1,050,000, 25% of which shall vest on each of the
- $450,000 — nt of stock options (Options) valued at $450,000, 25% of which shall vest on the first a
Filing Documents
- d848371d8k.htm (8-K) — 27KB
- 0001193125-25-322704.txt ( ) — 135KB
- bmrn-20251211.xsd (EX-101.SCH) — 3KB
- bmrn-20251211_lab.xml (EX-101.LAB) — 17KB
- bmrn-20251211_pre.xml (EX-101.PRE) — 11KB
- d848371d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: December 17, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer